Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NVX-CoV2705
- Development stage
- Approved
- Lead developer
- Novavax
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
NVX-CoV2705 is a **recombinant protein-based COVID-19 vaccine** developed by Novavax as an updated version of its earlier prototype vaccine NVX-CoV2373. It is a **protein subunit biologic** composed of recombinant SARS-CoV-2 spike protein presented using Novavax's recombinant nanoparticle technology and formulated with the **Matrix-M** saponin-based adjuvant to enhance and broaden immune responses. The vaccine is designed to target the **JN.1 lineage of SARS-CoV-2** and is used for active immunization to prevent COVID-19. It has been commercialized under the brand name **Nuvaxovid**, with Novavax as the developer and Sanofi collaborating on commercialization in the United States.
- Brand names
- Nuvaxovid
- Other names
- JN.1 COVID-19 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on NVX-CoV2705.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NVX-CoV2705.